Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wim Veling

Showing results (131-140 of 152) with videos related to

Pageof 16
Sort By:
Schizophrenia Research|September 28, 2023
Risk factors for suicidality across psychosis vulnerability spectrumNils Malte Stephan, Eleonore Dorothée van Sprang, Jasper Xiao Ming Wiebenga, et al.
Psychological Medicine|October 29, 2025
Psychological side effects of antipsychotic medication after remission from first-episode psychosis: a HAMLETT ecological momentary assessment studyMatej Djordjevic, Shiral S Gangadin, Lieuwe de Haan, et al.
Psychological Medicine|January 2, 2026
Negative association between cognitive functioning and antipsychotic D<sub>2</sub> receptor occupancy, affinity, and dose after first episode psychosisPriscilla P Oomen, Shiral S Gangadin, Lieuwe de Haan, et al.
Schizophrenia Bulletin|July 17, 2025
The International Psychosis Epidemiology Consortium Virtual Databank-A Platform for Data Harmonization and Federated Analysis of Psychosis CohortsVera Brink, Natalia Tiles-Sar, Hannah Jongsma, et al.
Psychological Medicine|September 8, 2025
Dopamine D<sub>2/3</sub>R availability after discontinuation of antipsychotic treatment: a [<sup>11</sup>C]raclopride PET study in remitted first-episode psychosis patientsFranciska de Beer, Erik de Vries, Ben Wijnen, et al.
Plos One|July 19, 2019
"Please tell me what happened": A descriptive study on prevalence, disclosure and characteristics of victimization in people with a psychotic disorderBertine de Vries, Gerdina H M Pijnenborg, Elisabeth C D van der Stouwe, et al.
JAMA Psychiatry|October 1, 2025
Early Dose Reduction or Discontinuation vs Maintenance Antipsychotics After First Psychotic Episode Remission: A Randomized Clinical TrialIris E Sommer, Franciska de Beer, Shiral Gangadin, et al.
Schizophrenia Research|March 20, 2026
Genetic susceptibility of cardiometabolic outcomes in schizophrenia spectrum disordersChenxu Zhao, Bochao Lin, Elnaz Naderi, et al.
Nature Medicine|August 13, 2025
Virtual reality-based versus standard cognitive behavioral therapy for paranoia in schizophrenia spectrum disorders: a randomized controlled trialUlrik N Jeppesen, Ditte L Vernal, Anne Sofie Due, et al.
Pilot and Feasibility Studies|May 2, 2020
A cognitive remediation training for young adults with psychotic disorders to support their participation in education - study protocol for a pilot randomized controlled trialLana K M Otto, Jacomijn Hofstra, Michelle G Mullen, et al.
Pageof 16

Showing results (131-140 of 152) with videos related to

Sort By:
Pageof 16
Schizophrenia Research|September 28, 2023
Risk factors for suicidality across psychosis vulnerability spectrumNils Malte Stephan, Eleonore Dorothée van Sprang, Jasper Xiao Ming Wiebenga, et al.
Psychological Medicine|October 29, 2025
Psychological side effects of antipsychotic medication after remission from first-episode psychosis: a HAMLETT ecological momentary assessment studyMatej Djordjevic, Shiral S Gangadin, Lieuwe de Haan, et al.
Psychological Medicine|January 2, 2026
Negative association between cognitive functioning and antipsychotic D<sub>2</sub> receptor occupancy, affinity, and dose after first episode psychosisPriscilla P Oomen, Shiral S Gangadin, Lieuwe de Haan, et al.
Schizophrenia Bulletin|July 17, 2025
The International Psychosis Epidemiology Consortium Virtual Databank-A Platform for Data Harmonization and Federated Analysis of Psychosis CohortsVera Brink, Natalia Tiles-Sar, Hannah Jongsma, et al.
Psychological Medicine|September 8, 2025
Dopamine D<sub>2/3</sub>R availability after discontinuation of antipsychotic treatment: a [<sup>11</sup>C]raclopride PET study in remitted first-episode psychosis patientsFranciska de Beer, Erik de Vries, Ben Wijnen, et al.
Plos One|July 19, 2019
"Please tell me what happened": A descriptive study on prevalence, disclosure and characteristics of victimization in people with a psychotic disorderBertine de Vries, Gerdina H M Pijnenborg, Elisabeth C D van der Stouwe, et al.
JAMA Psychiatry|October 1, 2025
Early Dose Reduction or Discontinuation vs Maintenance Antipsychotics After First Psychotic Episode Remission: A Randomized Clinical TrialIris E Sommer, Franciska de Beer, Shiral Gangadin, et al.
Schizophrenia Research|March 20, 2026
Genetic susceptibility of cardiometabolic outcomes in schizophrenia spectrum disordersChenxu Zhao, Bochao Lin, Elnaz Naderi, et al.
Nature Medicine|August 13, 2025
Virtual reality-based versus standard cognitive behavioral therapy for paranoia in schizophrenia spectrum disorders: a randomized controlled trialUlrik N Jeppesen, Ditte L Vernal, Anne Sofie Due, et al.
Pilot and Feasibility Studies|May 2, 2020
A cognitive remediation training for young adults with psychotic disorders to support their participation in education - study protocol for a pilot randomized controlled trialLana K M Otto, Jacomijn Hofstra, Michelle G Mullen, et al.
Pageof 16